410 related articles for article (PubMed ID: 31999714)
41. Prospective analysis of LDL-C goal achievement and self-reported medication adherence among statin users in primary care.
Bermingham M; Hayden J; Dawkins I; Miwa S; Gibson D; McDonald K; Ledwidge M
Clin Ther; 2011 Sep; 33(9):1180-9. PubMed ID: 21840055
[TBL] [Abstract][Full Text] [Related]
42. Blood pressure and low-density lipoprotein cholesterol control status in Chinese hypertensive dyslipidemia patients during lipid-lowering therapy.
Yan X; Li Y; Dong Y; Wu Y; Li J; Bian R; Hu D
Lipids Health Dis; 2019 Jan; 18(1):32. PubMed ID: 30696435
[TBL] [Abstract][Full Text] [Related]
43. Cost Effectiveness of Achieving Targets of Low-Density Lipoprotein Particle Number Versus Low-Density Lipoprotein Cholesterol Level.
Grabner M; Winegar DA; Punekar RS; Quimbo RA; Cziraky MJ; Cromwell WC
Am J Cardiol; 2017 Feb; 119(3):404-409. PubMed ID: 27887691
[TBL] [Abstract][Full Text] [Related]
44. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).
Desai NR; Giugliano RP; Zhou J; Kohli P; Somaratne R; Hoffman E; Liu T; Scott R; Wasserman SM; Sabatine MS
J Am Coll Cardiol; 2014 Feb; 63(5):430-3. PubMed ID: 24161333
[TBL] [Abstract][Full Text] [Related]
45. FACTORS INFLUENCING ACHIEVEMENT OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL GOALS IN MEXICO: THE INTERNATIONAL CHOLESTEROL MANAGEMENT PRACTICE STUDY.
Bello-Chavolla OY; Aguilar-Salinas CA
Rev Invest Clin; 2019; 71(6):408-416. PubMed ID: 31823964
[TBL] [Abstract][Full Text] [Related]
46. Influence of baseline low-density lipoprotein cholesterol values on statin therapy persistence.
Citarella A; Linder M; Kieler H; Berglind IA; Sundström A; Wettermark B; Andersen M
Eur J Clin Pharmacol; 2016 Mar; 72(3):349-57. PubMed ID: 26671240
[TBL] [Abstract][Full Text] [Related]
47. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011-2012.
Wong ND; Young D; Zhao Y; Nguyen H; Caballes J; Khan I; Sanchez RJ
J Clin Lipidol; 2016; 10(5):1109-18. PubMed ID: 27678427
[TBL] [Abstract][Full Text] [Related]
48. Role of Lipid-Lowering Therapy in Low-Density Lipoprotein Cholesterol Goal Attainment: Focus on Patients With Acute Coronary Syndrome.
Wang Q; Liang C
J Cardiovasc Pharmacol; 2020 Dec; 76(6):658-670. PubMed ID: 33002965
[TBL] [Abstract][Full Text] [Related]
49. Risk factors affecting the failed low-density lipoprotein level achievement rate in working-age male population at high cardiovascular risk.
Momo K; Yasu T; Yasui H; Kuroda SI
J Clin Pharm Ther; 2019 Oct; 44(5):715-719. PubMed ID: 31062402
[TBL] [Abstract][Full Text] [Related]
50. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
51. Prior adherence to recommended lipid control targets in patients admitted for acute coronary syndrome.
Milà L; Barrabés JA; Lidón RM; Sambola A; Bañeras J; Oristrell G; Rafecas A; García-Dorado D
Rev Esp Cardiol (Engl Ed); 2020 May; 73(5):376-382. PubMed ID: 31706709
[TBL] [Abstract][Full Text] [Related]
52. Results of retrospective chart review to determine improvement in lipid goal attainment in patients treated by high-volume prescribers of lipid-modifying drugs.
Stacy TA; Egger A
J Manag Care Pharm; 2006; 12(9):745-51. PubMed ID: 17249907
[TBL] [Abstract][Full Text] [Related]
53. Exploring the gap between National Cholesterol Education Program guidelines and clinical practice in secondary care: results of a cross-sectional study involving over 10 000 patients followed in different specialty settings across Italy.
Rapezzi C; Biagini E; Bellis P; Cafiero M; Velussi M; Ceriello A; Cooke RM; Schweiger C;
J Cardiovasc Med (Hagerstown); 2008 Sep; 9(9):878-87. PubMed ID: 18695423
[TBL] [Abstract][Full Text] [Related]
54. Achievement of LDL-C goals depends on baseline LDL-C and choice and dose of statin: an analysis from the VOYAGER database.
Palmer MK; Nicholls SJ; Lundman P; Barter PJ; Karlson BW
Eur J Prev Cardiol; 2013 Dec; 20(6):1080-7. PubMed ID: 23644489
[TBL] [Abstract][Full Text] [Related]
55. Association Between Achieved Low-Density Lipoprotein Levels and Major Adverse Cardiac Events in Patients With Stable Ischemic Heart Disease Taking Statin Treatment.
Leibowitz M; Karpati T; Cohen-Stavi CJ; Feldman BS; Hoshen M; Bitterman H; Suissa S; Balicer RD
JAMA Intern Med; 2016 Aug; 176(8):1105-13. PubMed ID: 27322095
[TBL] [Abstract][Full Text] [Related]
56. Statins for treatment of dyslipidemia in chronic kidney disease.
Shurraw S; Tonelli M
Perit Dial Int; 2006; 26(5):523-39. PubMed ID: 16973506
[TBL] [Abstract][Full Text] [Related]
57. Drug utilization patterns and cardiovascular outcomes in elderly patients newly initiated on atorvastatin or simvastatin.
Swindle JP; Potash J; Kulakodlu M; Kuznik A; Buikema A
Am J Geriatr Pharmacother; 2011 Dec; 9(6):471-82. PubMed ID: 22019005
[TBL] [Abstract][Full Text] [Related]
58. Baseline Predictors of Low-Density Lipoprotein Cholesterol and Systolic Blood Pressure Goal Attainment After 1 Year in the ISCHEMIA Trial.
Newman JD; Alexander KP; Gu X; O'Brien SM; Boden WE; Govindan SC; Senior R; Moorthy N; Rezende PC; Demkow M; Lopez-Sendon JL; Bockeria O; Pandit N; Gosselin G; Stone PH; Spertus JA; Stone GW; Fleg JL; Hochman JS; Maron DJ
Circ Cardiovasc Qual Outcomes; 2019 Nov; 12(11):e006002. PubMed ID: 31718297
[TBL] [Abstract][Full Text] [Related]
59. Quantifying Unmet Need in Statin-Treated Hyperlipidemia Patients and the Potential Benefit of Further LDL-C Reduction Through an EHR-Based Retrospective Cohort Study.
Schleyer T; Hui S; Wang J; Zhang Z; Knapp K; Baker J; Chase M; Boggs R; Simpson RJ
J Manag Care Spec Pharm; 2019 May; 25(5):544-554. PubMed ID: 31039062
[TBL] [Abstract][Full Text] [Related]
60. Prevalence and risk distribution of residual dyslipidemia in statin-treated patients in Greece.
Liberopoulos E; Vlasserou F; Mitrogianni Z; Papageorgantas I; Elisaf M;
Angiology; 2012 Apr; 63(3):184-93. PubMed ID: 21676964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
